Device Trial Radar · NCT07629557
Evaluate the Safety and Feasibility of Same-Day Bilateral Epithelium-On Corneal Cross-Linking for Keratoconus
Last checked: Nov 19, 2026Latest source record: Jun 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
15
Planned (sponsor's estimate)
Start
May 11, 2026
Primary completion
Sep 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- Glaukos CorporationPublic (GKOS)
- Sponsor type
- Industry
- First posted
- Jun 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 13 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Clinical trial to evaluate the safety and feasibility of corneal cross-linking in both eyes on the same day in subjects with keratoconus.
Conditions
- Keratoconus
Interventions
Riboflavin Ophthalmic SolutionsDrug
Riboflavin Ophthalmic Solutions
UV-A Irradiation SystemDevice
O2n UV-A Irradiation System
Primary outcomes
What the sponsor says the trial is designed to measure.
- Successful completion of bilateral epithelium-on corneal collagen cross-linking.Time frame: Approximately 2.5 Months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Glaukos Investigative Site
Westerville, Ohio · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.